Tarsus Pharmaceuticals, Inc. 8K

Tarsus Pharmaceuticals reported strong Q2 2026 results with higher XDEMVY sales and raised guidance, while advancing its pipeline, completing the iRenix acquisition, signing an agreement to acquire Alkeus Pharmaceuticals, and arranging a $125 million private placement financing.

On August 6, 2026, Tarsus Pharmaceuticals, Inc. reported strong second quarter 2026 financial results highlighted by XDEMVY net product sales of $173.9 million (up more than 69% year-over-year) and raised its full-year 2026 XDEMVY sales guidance to $685–705 million, while also announcing continued commercial traction from direct-to-consumer campaigns, advancement of multiple clinical programs, completion of the acquisition of iRenix Medical, entry into an agreement to acquire Alkeus Pharmaceuticals to expand its retina pipeline with the Phase 3 ALK-001 program for Stargardt disease, and the pricing of a $125 million private placement financing, all supported by a cash, cash equivalents, and marketable securities balance of $449.7 million and a reduced net loss of $18.6 million for the quarter.

Filing Facts

CIK

1819790

Ticker

TARS

Form

8K

Source Type

fda

Accession

0001819790-26-000063

Alert Tier

7